Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases
Source abstract
Abstract
Infectious diseases, particularly life-threatening pathogens such as small pox and influenza, have substantial implications on public health and global economies. Vaccination is a key approach to combat existing and emerging pathogens. Immunological memory is an essential characteristic used to evaluate vaccine efficacy and durability and the basis for the long-term effects of vaccines in protecting against future infections; however, optimizing the potency, improving the quality, and enhancing the durability of immune responses remains challenging and a focus for research involving investigation of nanovaccine technologies. In this review, we describe how nanovaccines can address the challenges for conventional vaccines in stimulating adaptive immune memory responses to protect against reinfection. We discuss protein and nonprotein nanoparticles as useful antigen platforms, including those with highly ordered and repetitive antigen array presentation to enhance immunogenicity through cross-linking with multiple B cell receptors, and with a focus on antigen properties. In addition, we describe how nanoadjuvants can improve immune responses by providing enhanced access to lymph nodes, lymphnode targeting, germinal center retention, and long-lasting immune response generation. Nanotechnology has the advantage to facilitate vaccine induction of long-lasting immunity against infectious diseases, now and in the future.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune responses and vaccinations · Immunotherapy and Immune Responses · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, P.R. China
University of Chinese Academy of Sciences, Beijing 100049, P.R. China
Institute for Advanced Study, Shenzhen University, Shenzhen 518060, P.R. China
Funding
National Key Research and Development Program of China · Special Project for Research and Development in Key areas of Guangdong Province · National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.1016/S1473-3099(12)70121-410.1016/S1473-3099(12)70121-4 ↗
2. WHO Coronavirus (COVID-19) Dashboard. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ (accessed in November 2023).
3. 10.1016/j.addr.2017.04.00810.1016/j.addr.2017.04.008 ↗
4. 10.1126/science.aay648510.1126/science.aay6485 ↗
5. 10.1016/j.immuni.2020.03.00710.1016/j.immuni.2020.03.007 ↗
6. 10.1086/59056710.1086/590567 ↗
7. 10.1016/j.immuni.2010.10.00810.1016/j.immuni.2010.10.008 ↗
8. 10.1016/j.chom.2018.12.00610.1016/j.chom.2018.12.006 ↗
9. 10.1038/nri308510.1038/nri3085 ↗
10. 10.1056/NEJMms121540010.1056/NEJMms1215400 ↗
11. 10.3389/fimmu.2018.0196310.3389/fimmu.2018.01963 ↗
12. 10.1038/s41565-020-00790-310.1038/s41565-020-00790-3 ↗
13. 10.1038/d41586-019-02751-w10.1038/d41586-019-02751-w ↗
14. 10.1126/science.aaz843210.1126/science.aaz8432 ↗
15. 10.1016/j.actbio.2020.03.02010.1016/j.actbio.2020.03.020 ↗
16. 10.1038/ni.203910.1038/ni.2039 ↗
17. 10.1038/s41578-021-00372-210.1038/s41578-021-00372-2 ↗
18. 10.1016/j.cell.2020.09.01310.1016/j.cell.2020.09.013 ↗
19. 10.1136/jitc-2022-00495310.1136/jitc-2022-004953 ↗
20. 10.1111/all.1527110.1111/all.15271 ↗
21. 10.1016/S0140-6736(21)01642-110.1016/S0140-6736(21)01642-1 ↗
22. 10.1056/NEJMoa211458310.1056/NEJMoa2114583 ↗
23. 10.1038/s41467-017-01901-w10.1038/s41467-017-01901-w ↗
24. 10.1038/d41586-021-01557-z10.1038/d41586-021-01557-z ↗
25. 10.1002/eji.20204901210.1002/eji.202049012 ↗
26. 10.1034/j.1600-065X.2000.917309.x10.1034/j.1600-065X.2000.917309.x ↗
27. 10.1016/j.jaci.2009.09.01710.1016/j.jaci.2009.09.017 ↗
28. 10.1016/j.it.2005.02.00110.1016/j.it.2005.02.001 ↗
29. 10.1111/imr.1264710.1111/imr.12647 ↗
30. 10.1038/s41577-020-0285-610.1038/s41577-020-0285-6 ↗
31. 10.1126/science.aaf109810.1126/science.aaf1098 ↗
32. 10.1016/j.cell.2016.09.03410.1016/j.cell.2016.09.034 ↗
33. 10.1016/j.immuni.2020.12.00910.1016/j.immuni.2020.12.009 ↗
34. 10.1016/j.immuni.2020.04.01210.1016/j.immuni.2020.04.012 ↗
35. 10.1038/nri.2015.310.1038/nri.2015.3 ↗
36. 10.3389/fimmu.2019.0160510.3389/fimmu.2019.01605 ↗
37. 10.1126/sciimmunol.abl910510.1126/sciimmunol.abl9105 ↗
38. 10.1038/s41556-021-00690-110.1038/s41556-021-00690-1 ↗
39. 10.1038/s41586-021-03647-410.1038/s41586-021-03647-4 ↗
40. 10.1016/j.cell.2021.06.00510.1016/j.cell.2021.06.005 ↗
41. 10.1016/j.cell.2022.05.02210.1016/j.cell.2022.05.022 ↗
42. 10.1172/JCI15799010.1172/JCI157990 ↗
43. 10.1038/nature2463310.1038/nature24633 ↗
44. 10.1038/s41586-021-03841-410.1038/s41586-021-03841-4 ↗
45. 10.1073/pnas.220633311910.1073/pnas.2206333119 ↗
46. 10.1038/nri380210.1038/nri3802 ↗
47. 10.1038/s41392-022-00937-910.1038/s41392-022-00937-9 ↗
48. 10.1016/j.vaccine.2015.11.06210.1016/j.vaccine.2015.11.062 ↗
49. 10.1038/s41421-021-00360-410.1038/s41421-021-00360-4 ↗
50. 10.1128/JVI.01219-1410.1128/JVI.01219-14 ↗
51. 10.1016/j.coviro.2013.05.00310.1016/j.coviro.2013.05.003 ↗
52. 10.1128/CMR.00084-1810.1128/CMR.00084-18 ↗
53. 10.1586/14760584.2015.108106710.1586/14760584.2015.1081067 ↗
54. 10.1128/msphere.00892-2110.1128/msphere.00892-21 ↗
55. 10.1038/s41577-020-00434-610.1038/s41577-020-00434-6 ↗
56. 10.1172/JCI15770710.1172/JCI157707 ↗
57. 10.1093/infdis/jiy13510.1093/infdis/jiy135 ↗
58. 10.1007/978-1-4939-6445-1_110.1007/978-1-4939-6445-1_1 ↗
59. 10.1016/j.vaccine.2010.07.02010.1016/j.vaccine.2010.07.020 ↗
60. 10.1002/cmdc.20120048710.1002/cmdc.201200487 ↗
61. 10.1016/j.it.2008.09.00610.1016/j.it.2008.09.006 ↗
62. 10.1038/nri251010.1038/nri2510 ↗
63. 10.1126/science.108992610.1126/science.1089926 ↗
64. 10.1111/1348-0421.1302410.1111/1348-0421.13024 ↗
65. 10.1038/s41564-020-00789-510.1038/s41564-020-00789-5 ↗
66. 10.1016/j.coviro.2019.02.00210.1016/j.coviro.2019.02.002 ↗
67. 10.1097/CJI.0b013e31818f13c410.1097/CJI.0b013e31818f13c4 ↗
68. 10.1016/j.vaccine.2005.11.05710.1016/j.vaccine.2005.11.057 ↗
69. 10.1007/s13238-015-0164-210.1007/s13238-015-0164-2 ↗
70. 10.4049/jimmunol.160177510.4049/jimmunol.1601775 ↗
71. 10.1016/j.smim.2021.10150510.1016/j.smim.2021.101505 ↗
72. 10.1126/scitranslmed.300376310.1126/scitranslmed.3003763 ↗
73. 10.1038/nbt.261210.1038/nbt.2612 ↗
74. 10.1016/j.ymthe.2019.01.02010.1016/j.ymthe.2019.01.020 ↗
75. 10.1038/s41573-021-00283-510.1038/s41573-021-00283-5 ↗
76. 10.1007/s00125-018-4593-310.1007/s00125-018-4593-3 ↗
77. 10.1038/s41551-022-00886-210.1038/s41551-022-00886-2 ↗
78. 10.3389/fphar.2021.68228610.3389/fphar.2021.682286 ↗
79. 10.1038/s41565-020-0739-910.1038/s41565-020-0739-9 ↗
80. 10.1073/pnas.182016511610.1073/pnas.1820165116 ↗
81. 10.1016/j.addr.2021.11391410.1016/j.addr.2021.113914 ↗
82. 10.1093/oxfordjournals.aje.a12095510.1093/oxfordjournals.aje.a120955 ↗
83. 10.1038/nature1296610.1038/nature12966 ↗
84. 10.1146/annurev-med-121217-09423410.1146/annurev-med-121217-094234 ↗
85. 10.1038/nature1340410.1038/nature13404 ↗
86. 10.1038/nrmicro289310.1038/nrmicro2893 ↗
87. 10.1038/s41423-020-0400-410.1038/s41423-020-0400-4 ↗
88. 10.1016/j.cell.2020.10.04310.1016/j.cell.2020.10.043 ↗
89. 10.1038/nri286810.1038/nri2868 ↗
90. 10.4049/jimmunol.180.9.581610.4049/jimmunol.180.9.5816 ↗
91. 10.1146/annurev.immunol.15.1.23510.1146/annurev.immunol.15.1.235 ↗
92. 10.1111/j.1365-2796.2011.02367.x10.1111/j.1365-2796.2011.02367.x ↗
93. 10.1016/j.vaccine.2019.11.03610.1016/j.vaccine.2019.11.036 ↗
94. 10.1038/nrmicro287210.1038/nrmicro2872 ↗
95. 10.1371/journal.pbio.300016410.1371/journal.pbio.3000164 ↗
96. 10.1016/j.csbj.2015.11.00110.1016/j.csbj.2015.11.001 ↗
97. 10.1186/s12951-021-00806-710.1186/s12951-021-00806-7 ↗
98. 10.1016/j.vaccine.2013.11.06910.1016/j.vaccine.2013.11.069 ↗
99. 10.1021/acsnano.2c0128310.1021/acsnano.2c01283 ↗
100. 10.1002/bit.2786410.1002/bit.27864 ↗